Quantbot Technologies LP Sells 44,148 Shares of Progyny, Inc. (NASDAQ:PGNY)

Quantbot Technologies LP decreased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 33.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,316 shares of the company's stock after selling 44,148 shares during the quarter. Quantbot Technologies LP owned approximately 0.10% of Progyny worth $1,489,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of PGNY. Signaturefd LLC boosted its position in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Progyny during the 4th quarter worth approximately $339,000. First Eagle Investment Management LLC bought a new position in Progyny during the fourth quarter worth $2,500,000. River Road Asset Management LLC acquired a new stake in Progyny in the fourth quarter worth $25,529,000. Finally, Amundi bought a new stake in Progyny in the fourth quarter valued at $102,000. Institutional investors own 94.93% of the company's stock.

Progyny Price Performance

Shares of Progyny stock traded down $0.41 during trading hours on Friday, hitting $21.90. 1,282,849 shares of the company's stock traded hands, compared to its average volume of 1,696,184. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.76, a PEG ratio of 2.39 and a beta of 1.41. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $37.92. The company has a fifty day simple moving average of $22.05 and a 200-day simple moving average of $18.58.

Remove Ads

Analysts Set New Price Targets

Several analysts have recently commented on the company. Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Finally, Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $24.82.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.